Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 12/20 | 0.42 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.39 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.39 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.39 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16341083 | 0.84 | SCN9A (0.41) | MRGPRX4SCN9APLAAT3PLAAT5PLAAT2 | |
| SCHEMBL875444 | 0.84 | MRGPRX4 (0.42) | MRGPRX4SCN9APLAAT3PLAAT5PLAAT2 | |
| SCHEMBL15900993 | 0.82 | HDAC1 (0.37) | GRM5CHRNB2CHRNA4 | |
| SCHEMBL876627 | 0.81 | KIF11 (0.33) | — | |
| SCHEMBL29769062 | 0.81 | LOXL2 (0.42) | ALOX5APFEN1 | |
| SCHEMBL15901459 | 0.81 | LOXL2 (0.42) | ALOX5APFEN1 | |
| SCHEMBL23174296 | 0.80 | PLA2G7 (0.35) | SCN9ASCN10A | |
| SCHEMBL30026194 | 0.80 | FFAR4 (0.42) | GRM5 | |
| SCHEMBL15096480 | 0.80 | FFAR4 (0.42) | GRM5 | |
| SCHEMBL15901258 | 0.80 | NPC1 (0.40) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4174070-B1 | TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF | NEUSCO BIOTECH LTD (CN) | 2025-10-29 | — | — | EP | disclosed |
| CN-119161343-A | Bridged pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119143780-A | Lp-PLA2 inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119080800-A | Tricyclic pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof | 上海深势唯思科技有限责任公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240300965-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-12 | — | — | US | disclosed |
| US-11999746-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| CN-113912622-B | Tricyclic pyrimidinone compounds, methods of making, compositions and uses thereof | 上海纽思克生物科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | NEUSCO BIOTECH LIMITED (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013014185-A1 | BICYCLIC PYRIMIDONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| WO-2013013503-A1 | 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
| US-20130030012-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300965-A1 | COMPOUNDS | PLAAT2, PLA2G12A, PLA2G1B | MRGPRX4 803/4885SCN9A 2966/4885PLAAT3 32/4885 |
| US-20130030012-A1 | COMPOUNDS | LPCAT1, PLA2G7, PLAAT2 | MRGPRX4 680/4885SCN9A 4057/4885PLAAT3 40/4885 |
| US-11999746-B2 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | MRGPRX4 803/4885SCN9A 2966/4885PLAAT3 32/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | MRGPRX4 1030/4885SCN9A 4613/4885PLAAT3 65/4885 |
| US-20230357268-A1 | PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION | PLA2G1B, PLA2G4B, PLA2G5 | MRGPRX4 770/4885SCN9A 2998/4885PLAAT3 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.